GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease

[1]  F. Willard,et al.  The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets , 2023, Nature Metabolism.

[2]  D. Drucker,et al.  Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1 , 2022, Nature Reviews Endocrinology.

[3]  R. DiMarchi,et al.  Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes , 2022, Frontiers in Endocrinology.

[4]  R. Eckel,et al.  ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes. , 2022, Diabetes care.

[5]  R. Eckel,et al.  Comprehensive Care Models for Cardiometabolic Disease , 2021, Current Cardiology Reports.

[6]  L. Groop,et al.  Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness. , 2020, Diabetes care.

[7]  Philipp E. Geyer,et al.  Plasma proteome profiles treatment efficacy of incretin dual agonism in diet‐induced obese female and male mice , 2020, Diabetes, obesity & metabolism.

[8]  M. Taskinen,et al.  The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes , 2020, Diabetes, obesity & metabolism.

[9]  A. Feuchtinger,et al.  The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling , 2020, Cell metabolism.

[10]  D. Drucker,et al.  Proglucagon-Derived Peptides, GIP and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue. , 2019, Endocrinology.

[11]  M. Tschöp,et al.  Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism , 2018, Molecular metabolism.

[12]  R. Gimeno,et al.  Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial , 2018, The Lancet.

[13]  C. Lamendola,et al.  American Heart Association Diabetes and Cardiometabolic Health Summit: Summary and Recommendations , 2018, Journal of the American Heart Association.

[14]  M. Tschöp,et al.  The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. , 2017, Cell metabolism.

[15]  H. Fuchs,et al.  Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease , 2016, Cell.

[16]  Monther Alhamdoosh,et al.  RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR , 2016, F1000Research.

[17]  J. Holst,et al.  The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss , 2016, Nutrition & Diabetes.

[18]  M. Tschöp,et al.  Reappraisal of GIP Pharmacology for Metabolic Diseases. , 2016, Trends in molecular medicine.

[19]  T. Hansen,et al.  Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study. , 2016, The Journal of clinical endocrinology and metabolism.

[20]  J. Holst,et al.  Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects , 2014, International Journal of Obesity.

[21]  S. Luquet,et al.  High-Density Lipoprotein Maintains Skeletal Muscle Function by Modulating Cellular Respiration in Mice , 2013, Circulation.

[22]  Bin Yang,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[23]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans , 2010, Diabetes.

[24]  D. R. Faber,et al.  Role of adipose tissue in haemostasis, coagulation and fibrinolysis , 2009, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[25]  Udo Hoffmann,et al.  Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study , 2007, Circulation.

[26]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[27]  M. Nauck,et al.  Effect of Exogenous or Endogenous Gastric Inhibitory Polypeptide (GIP) on Plasma Triglyceride Responses in Rats , 1991, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[28]  R. Unger,et al.  Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. , 1981, The Journal of clinical investigation.

[29]  Monther Alhamdoosh,et al.  RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR , 2016, F1000Research.